Literature DB >> 25005891

Dual quantification of dapivirine and maraviroc in cervicovaginal secretions from ophthalmic tear strips and polyester-based swabs via liquid chromatographic-tandem mass spectrometric (LC-MS/MS) analysis.

Teresa L Parsons1, Joshua F Emory1, Lauren A Seserko1, Wutyi S Aung1, Mark A Marzinke2.   

Abstract

BACKGROUND: Topical microbicidal agents are being actively pursued as a modality to prevent HIV viral transmission during sexual intercourse. Quantification of antiretroviral agents in specimen sources where antiviral activity is elicited is critical, and drug measurements in cervicovaginal fluid can provide key information on local drug concentrations. Two antiretroviral drugs, dapivirine and maraviroc, have gained interest as vaginal microbicidal agents, and rugged methods are required for their quantification in cervicovaginal secretions.
METHODS: Cervicovaginal fluid spiked with dapivirine and maraviroc were applied to ophthalmic tear strips or polyester-based swabs to mimic collection procedures used in clinical studies. Following sample extraction and the addition of isotopically labeled internal standards, samples were subjected to liquid chromatographic-tandem mass spectrometric (LC-MS/MS) analysis using a Waters BEH C8, 50mm×2.1mm, 1.7μm particle size column, on an API 4000 mass analyzer operated in selective reaction monitoring mode. The method was validated according to FDA Bioanalytical Method Validation guidelines.
RESULTS: Due to the disparate saturation capacity of the tested collection devices, the analytical measuring ranges for dapivirine and maravirocin cervicovaginal fluid on the ophthalmic tear strip were 0.05-25ng/tear strip, and 0.025-25ng/tear strip, respectively. As for the polyester-based swab, the analytical measuring ranges were 0.25-125ng/swab for dapivirine and 0.125-125ng/swab for maraviroc. Dilutional studies were performed for both analytes to extended ranges of 25,000ng/tear strip and 11,250ng/swab. Standard curves were generated via weighted (1/x(2)) linear or quadratic regression of calibrators. Precision, accuracy, stability and matrix effects studies were all performed and deemed acceptable according to the recommendations of the FDA Bioanalytical Method Validation guidelines.
CONCLUSIONS: A rugged LC-MS/MS method for the dual quantification of dapivirine and maraviroc in cervicovaginal fluid using two unique collection devices has been developed and validated. The described method meets the criteria to support large research trials.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antiretroviral; Cervicovaginal fluid; Dapivirine; Maraviroc; Validation

Mesh:

Substances:

Year:  2014        PMID: 25005891      PMCID: PMC4143664          DOI: 10.1016/j.jpba.2014.06.018

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  31 in total

Review 1.  A proposal for quality standards for measuring medication adherence in research.

Authors:  Ann Bartley Williams; K Rivet Amico; Carol Bova; Julie A Womack
Journal:  AIDS Behav       Date:  2013-01

Review 2.  Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract.

Authors:  Laura J Else; Stephen Taylor; David J Back; Saye H Khoo
Journal:  Antivir Ther       Date:  2011

3.  Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Authors:  Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor
Journal:  Science       Date:  2010-07-19       Impact factor: 47.728

4.  Pharmacokinetics of a CCR5 inhibitor in rhesus macaques following vaginal, rectal and oral application.

Authors:  R Karl Malcolm; Deborah Lowry; Peter Boyd; Leslie Geer; Ronald S Veazey; Laurie Goldman; P J Klasse; Robin J Shattock; John P Moore
Journal:  J Antimicrob Chemother       Date:  2013-12-30       Impact factor: 5.790

5.  Matrix effect in quantitative LC/MS/MS analyses of biological fluids: a method for determination of finasteride in human plasma at picogram per milliliter concentrations.

Authors:  B K Matuszewski; M L Constanzer; C M Chavez-Eng
Journal:  Anal Chem       Date:  1998-03-01       Impact factor: 6.986

6.  Development and bioanalytical validation of a liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method for the quantification of the CCR5 antagonist maraviroc in human plasma.

Authors:  Joshua F Emory; Lauren A Seserko; Mark A Marzinke
Journal:  Clin Chim Acta       Date:  2014-02-19       Impact factor: 3.786

7.  Topical prophylaxis for HIV prevention in women: becoming a reality.

Authors:  Natasha A Verma; Anna C Lee; Betsy C Herold; Marla J Keller
Journal:  Curr HIV/AIDS Rep       Date:  2011-06       Impact factor: 5.071

8.  Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women.

Authors:  Annalene Nel; Shanique Smythe; Katherine Young; Karl Malcolm; Clare McCoy; Zeda Rosenberg; Joseph Romano
Journal:  J Acquir Immune Defic Syndr       Date:  2009-08-01       Impact factor: 3.731

9.  Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring.

Authors:  J Romano; B Variano; P Coplan; J Van Roey; K Douville; Z Rosenberg; M Temmerman; H Verstraelen; L Van Bortel; S Weyers; M Mitchnick
Journal:  AIDS Res Hum Retroviruses       Date:  2009-05       Impact factor: 2.205

10.  Postexposure prophylaxis, preexposure prophylaxis or universal test and treat: the strategic use of antiretroviral drugs to prevent HIV acquisition and transmission.

Authors:  Jonathan Weber; Roger Tatoud; Sarah Fidler
Journal:  AIDS       Date:  2010-10       Impact factor: 4.177

View more
  14 in total

1.  Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings: A Double-Blind Randomized Trial.

Authors:  Beatrice A Chen; Lori Panther; Mark A Marzinke; Craig W Hendrix; Craig J Hoesley; Ariane van der Straten; Marla J Husnik; Lydia Soto-Torres; Annalene Nel; Sherri Johnson; Nicola Richardson-Harman; Lorna K Rabe; Charlene S Dezzutti
Journal:  J Acquir Immune Defic Syndr       Date:  2015-11-01       Impact factor: 3.731

2.  Validation and implementation of an ultrasensitive liquid chromatographic-tandem mass spectrometric (LC-MS/MS) assay for dapivirine quantitation in breast milk.

Authors:  Madhuri Manohar; Mark A Marzinke
Journal:  Clin Biochem       Date:  2019-12-13       Impact factor: 3.281

3.  A Randomized, Double Blind, Placebo-Controlled, Phase 1 Safety, and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults (MTN-026).

Authors:  Ross D Cranston; Elizabeth Brown; José Bauermeister; Eileen F Dunne; Craig Hoesley; Ken Ho; Sherri Johnson; Jonathan Lucas; Clara Dominguez-Islas; Holly Gundacker; Melissa Peda; Cindy E Jacobson; Lindsay Kramzer; Devika Singh; Charlene S Dezzutti; Ratiya Pamela Kunjara Na Ayudhya; Rhonda M Brand; Lin Wang; Mark A Marzinke; Jeanna Piper; Bríd Devlin; Jeremy Nuttall; Ian McGowan; Craig W Hendrix
Journal:  AIDS Res Hum Retroviruses       Date:  2021-12-06       Impact factor: 1.723

4.  A Randomized, Open-Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel (the CHARM-03 Study).

Authors:  Ian M McGowan; Sylvain Chawki; Craig W Hendrix; Peter A Anton; Mark A Marzinke; Rhonda M Brand; Jarret C Engstrom; Lisa C Rohan; Kaleab Z Abebe; Nicola Richardson-Harman; Aaron Siegel; Alex Reinhart; John Steytler; Ronald Stall; Hans Spiegel; Beatrice Chen; Sharon L Achilles; Cindy E Jacobson; Elena Khanukova; Ross D Cranston
Journal:  AIDS Res Hum Retroviruses       Date:  2021-09-14       Impact factor: 1.723

5.  Phase 2a Safety, Pharmacokinetics, and Acceptability of Dapivirine Vaginal Rings in US Postmenopausal Women.

Authors:  Beatrice A Chen; Jingyang Zhang; Holly M Gundacker; Craig W Hendrix; Craig J Hoesley; Robert A Salata; Charlene S Dezzutti; Ariane van der Straten; Wayne B Hall; Cindy E Jacobson; Sherri Johnson; Ian McGowan; Annalene M Nel; Lydia Soto-Torres; Mark A Marzinke
Journal:  Clin Infect Dis       Date:  2019-03-19       Impact factor: 9.079

6.  Combination Pod-Intravaginal Ring Delivers Antiretroviral Agents for HIV Prophylaxis: Pharmacokinetic Evaluation in an Ovine Model.

Authors:  John A Moss; Irina Butkyavichene; Scott A Churchman; Manjula Gunawardana; Rob Fanter; Christine S Miller; Flora Yang; Jeremiah T Easley; Mark A Marzinke; Craig W Hendrix; Thomas J Smith; Marc M Baum
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

7.  A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal Film.

Authors:  Katherine E Bunge; Charlene S Dezzutti; Lisa C Rohan; Craig W Hendrix; Mark A Marzinke; Nicola Richardson-Harman; Bernard J Moncla; Brid Devlin; Leslie A Meyn; Hans M L Spiegel; Sharon L Hillier
Journal:  J Acquir Immune Defic Syndr       Date:  2016-04-15       Impact factor: 3.731

8.  Optimising the collection of female genital tract fluid for cytokine analysis in pregnant women.

Authors:  C S Short; R Quinlan; P Bennett; R J Shattock; G P Taylor
Journal:  J Immunol Methods       Date:  2018-04-03       Impact factor: 2.303

9.  Phase 1 pharmacokinetics and safety study of extended duration dapivirine vaginal rings in the United States.

Authors:  Albert Y Liu; Clara Dominguez Islas; Holly Gundacker; Blazej Neradilek; Craig Hoesley; Ariane van der Straten; Craig W Hendrix; May Beamer; Cindy E Jacobson; Tara McClure; Tanya Harrell; Katherine Bunge; Brid Devlin; Jeremy Nuttall; Patrick Spence; John Steytler; Jeanna M Piper; Mark A Marzinke
Journal:  J Int AIDS Soc       Date:  2021-06       Impact factor: 6.707

10.  Pharmacodynamic correlations using fresh and cryopreserved tissue following use of vaginal rings containing dapivirine and/or maraviroc in a randomized, placebo controlled trial.

Authors:  Charlene S Dezzutti; Nicola Richardson-Harman; Lisa C Rohan; Mark A Marzinke; Craig J Hoesley; Lori Panther; Sherri Johnson; Jeremy P Nuttall; Annalene Nel; Beatrice A Chen
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.